Evidence map›Paper›PMID 28987935›Full record

ArticleAnalytical biochemistry2018

In situ measurements of mitochondrial matrix enzyme activities using plasma and mitochondrial membrane permeabilization agents.

Ajit S Divakaruni, Alexander Y Andreyev, George W Rogers, Anne N Murphy

Abstract read
In one paragraph

Article in Analytical biochemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Exogenous expression of ATP8, a mitochondrial encoded protein, from the nucleusMolecular therapy. Methods & clinical development · 2024
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Ajit S DivakaruniUniversity of California, Los Angeles, Department of Molecular and Medical Pharmacology, 650 Charles E. Young Dr. South, 23-305 Center for Health Sciences, Los Angeles, CA 90095-1735, United States. Electronic address: adivakaruni@mednet.ucla.edu.
Alexander Y AndreyevUniversity of California, San Diego, Department of Pharmacology, 9500 Gilman Drive #0636, La Jolla, CA 92093, United States.
George W RogersAgilent Technologies, 5301 Stevens Creek Blvd, Santa Clara, CA 95051, United States.
Anne N MurphyUniversity of California, San Diego, Department of Pharmacology, 9500 Gilman Drive #0636, La Jolla, CA 92093, United States.
University of California San Diego · USAgilent Technologies (United States) · USUniversity of California, Los Angeles · US

Funding

Targeting the mitochondrial pyruvate carrier to treat neurodegenerative diseaseR01NS087611 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHANG, GEOFFREY A, MURPHY, ANNE N. · 2014 to 2018
$2.9M
NINDS NIH HHS R01 NS087611
6 · The paper itself

Abstract

Activities of enzymes localized to the mitochondrial matrix of mammalian cells are often critical regulatory steps in cellular metabolism. As such, measurement of matrix enzyme activities in response to genetic modifications or drug interventions is often desired. However, measurements in intact cells are often hampered by the presence of other isozymes in the cytoplasm as well as the inability to deliver enzyme substrates across cellular membranes. Classic approaches to liberate matrix enzymes utilize harsh treatments that disrupt intracellular architecture or require significant starting material to allow mitochondrial isolation prior to sample extraction. We describe a method using permeabilization reagents for both the plasma and mitochondrial membranes to allow in situ measurement of matrix enzyme activities. It is applied to adherent cell monolayers in 96-well plates treated with perfringolysin O to permeabilize the plasma membrane and alamethicin to permeabilize the mitochondrial inner membrane. We present three examples validated with inhibitor sensitivity: (i) Complex I-mediated oxygen consumption driven by NADH, (ii) ATP hydrolysis by the F

Indexed as

A549 CellsBacterial ToxinsCell Membrane PermeabilityGlutaminaseHemolysin ProteinsHep G2 CellsHumansMitochondrial MembranesMitochondrial Proton-Translocating ATPasesNADOxygen ConsumptionBacterial ToxinsClostridium perfringens theta-toxinF1F0-ATP synthaseGlutaminaseHemolysin ProteinsMitochondrial Proton-Translocating ATPasesNADATP synthaseGlutaminaseMatrix enzyme activitiesOxygen consumption ratePermeabilized cellsPermeabilized mitochondria

Identifiers

PMID28987935
PMCPMC5882612
OpenAlexW2763067462

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.